AR036905A1 - Derivados del 3-azabiciclo[3.1.0]hexano, composiciones farmaceuticas que los contienen, su uso en un metodo para tratar un trastorno o afeccion en un mamifero, e intermediarios utiles para su sintesis - Google Patents

Derivados del 3-azabiciclo[3.1.0]hexano, composiciones farmaceuticas que los contienen, su uso en un metodo para tratar un trastorno o afeccion en un mamifero, e intermediarios utiles para su sintesis

Info

Publication number
AR036905A1
AR036905A1 ARP020103960A ARP020103960A AR036905A1 AR 036905 A1 AR036905 A1 AR 036905A1 AR P020103960 A ARP020103960 A AR P020103960A AR P020103960 A ARP020103960 A AR P020103960A AR 036905 A1 AR036905 A1 AR 036905A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally
cycloalkyl
heterocycloalkyl
halogen
Prior art date
Application number
ARP020103960A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR036905A1 publication Critical patent/AR036905A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/04—Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP020103960A 2001-10-22 2002-10-21 Derivados del 3-azabiciclo[3.1.0]hexano, composiciones farmaceuticas que los contienen, su uso en un metodo para tratar un trastorno o afeccion en un mamifero, e intermediarios utiles para su sintesis AR036905A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33851101P 2001-10-22 2001-10-22

Publications (1)

Publication Number Publication Date
AR036905A1 true AR036905A1 (es) 2004-10-13

Family

ID=23325099

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103960A AR036905A1 (es) 2001-10-22 2002-10-21 Derivados del 3-azabiciclo[3.1.0]hexano, composiciones farmaceuticas que los contienen, su uso en un metodo para tratar un trastorno o afeccion en un mamifero, e intermediarios utiles para su sintesis

Country Status (42)

Country Link
US (3) US7049335B2 (enExample)
EP (1) EP1440059B1 (enExample)
JP (2) JP4155522B2 (enExample)
KR (1) KR100621292B1 (enExample)
CN (1) CN100368398C (enExample)
AP (1) AP1816A (enExample)
AR (1) AR036905A1 (enExample)
AT (1) ATE392415T1 (enExample)
AU (1) AU2002329557B2 (enExample)
BR (1) BR0213464A (enExample)
CA (1) CA2463264C (enExample)
CR (1) CR7317A (enExample)
DE (1) DE60226161T2 (enExample)
DK (1) DK1440059T3 (enExample)
EA (1) EA006708B1 (enExample)
EC (1) ECSP045077A (enExample)
ES (1) ES2302839T3 (enExample)
GE (1) GEP20084300B (enExample)
GT (1) GT200200216A (enExample)
HN (1) HN2002000299A (enExample)
HR (1) HRP20040288A2 (enExample)
HU (1) HUP0401884A2 (enExample)
IL (2) IL161157A0 (enExample)
IS (1) IS7187A (enExample)
MA (1) MA27141A1 (enExample)
MX (1) MXPA04003730A (enExample)
MY (1) MY136580A (enExample)
NO (1) NO329092B1 (enExample)
NZ (1) NZ531807A (enExample)
OA (1) OA12711A (enExample)
PA (1) PA8556701A1 (enExample)
PE (1) PE20030610A1 (enExample)
PL (1) PL368919A1 (enExample)
PT (1) PT1440059E (enExample)
PY (1) PY0225353A (enExample)
RS (1) RS25104A (enExample)
SI (1) SI1440059T1 (enExample)
SV (1) SV2004001363A (enExample)
TN (1) TNSN04071A1 (enExample)
UA (1) UA75714C2 (enExample)
WO (1) WO2003035622A1 (enExample)
ZA (1) ZA200402172B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE410165T1 (de) 2001-04-18 2008-10-15 Euro Celtique Sa Nociceptin-analoga
JP4155522B2 (ja) * 2001-10-22 2008-09-24 ファイザー・プロダクツ・インク オピオイド受容体アンタゴニストとしての３−アザビシクロ（３．１．０）ヘキサン誘導体
BRPI0409307A (pt) * 2003-04-14 2006-04-25 Pfizer Prod Inc derivados de 3-azabiciclo[3.2.1]octano
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7153976B2 (en) * 2003-10-06 2006-12-26 Pfizer Inc. Purification process for an azabicyclo[3.1.0]hexane compound
EA009903B1 (ru) * 2003-10-14 2008-04-28 Пфайзер Продактс Инк. Бициклические [3.1.0] производные в качестве ингибиторов переносчиков глицина
AU2004281229A1 (en) * 2003-10-16 2005-04-28 Pfizer Products Inc. Preparation of 3-azabicyclo (3.1.0) hexane derivatives
ATE451364T1 (de) * 2004-02-23 2009-12-15 Glaxo Group Ltd Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
US7855294B2 (en) * 2004-03-05 2010-12-21 Banyu Pharmaceutical Co., Ltd. Cycloalkanopyridine derivative
CA2590182A1 (en) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. Indolomorphinan derivatives having carboxy at the 6'-position
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2008075162A2 (en) * 2006-12-15 2008-06-26 Pfizer Limited Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
US7947710B2 (en) * 2007-08-27 2011-05-24 Theravance, Inc. Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
ES2465621T3 (es) * 2007-08-27 2014-06-06 Theravance, Inc. Compuestos de heteroarilalquil-8-azabiciclo[3.2.1]octano, como antagonistas de los receptores opiodes mu
TWI423801B (zh) 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
US7902221B2 (en) * 2007-08-27 2011-03-08 Theravance, Inc. Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
BR112013007566A2 (pt) 2010-09-28 2016-08-02 Panacea Biotec Ltd novos compostos bicíclicos
DK3072884T3 (da) * 2013-11-20 2020-03-09 Sanwa Kagaku Kenkyusho Co 3-azabicyclo[3.1.0]hexanderivat og anvendelse deraf til medicinske formål
MX388953B (es) * 2015-05-20 2025-03-20 Ube Industries Cristal de sal de derivado de 3-azabiciclo[3.1.0]hexano novedoso y usos medicionales del mismo.
KR20190120212A (ko) 2017-03-02 2019-10-23 가부시키가이샤산와카가쿠켄큐쇼 알코올 사용 장해의 치료약

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2099214A (en) * 1937-11-16 Process fob forming the sulphuric
US2099216A (en) * 1934-05-04 1937-11-16 Frederick H Nass Metal testing machine
US3004340A (en) * 1959-09-24 1961-10-17 Bernice L Collins Kitchen utensil
US3078282A (en) * 1960-01-02 1963-02-19 Bayer Ag Anthraquinone dyestuffs
NZ224236A (en) 1987-04-16 1990-08-28 Lilly Co Eli Trans 3,4 pyridine derivatives and pharmaceutical compositions
JPH04155522A (ja) * 1990-10-19 1992-05-28 Nec Corp ファースト・イン・ランダム・アウト回路
CZ284993B6 (cs) 1991-03-29 1999-04-14 Eli Lilly And Company Derivát piperidinu
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
GB9725114D0 (en) * 1997-11-28 1998-01-28 Pfizer Ltd Treatment of pruritus
GB9810671D0 (en) 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912410D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US20020064825A1 (en) 2000-05-19 2002-05-30 Lewis Marilyn Evelyn Novel polypeptide
US20020025948A1 (en) * 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US20030207876A1 (en) * 2000-06-23 2003-11-06 Banks Bernard Joseph 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy
DE10042885A1 (de) * 2000-08-31 2002-03-14 Heidelberger Druckmasch Ag Bogentransportzylinder
JP4155522B2 (ja) 2001-10-22 2008-09-24 ファイザー・プロダクツ・インク オピオイド受容体アンタゴニストとしての３−アザビシクロ（３．１．０）ヘキサン誘導体
WO2003101963A1 (en) 2002-05-30 2003-12-11 Eli Lilly And Company Opioid receptor antagonists
US20040204453A1 (en) 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
US7056930B2 (en) 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
US20050043327A1 (en) 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7153976B2 (en) 2003-10-06 2006-12-26 Pfizer Inc. Purification process for an azabicyclo[3.1.0]hexane compound

Also Published As

Publication number Publication date
UA75714C2 (en) 2006-05-15
NO20041626L (no) 2004-05-26
AP1816A (en) 2008-01-04
CA2463264A1 (en) 2003-05-01
NZ531807A (en) 2006-03-31
EA006708B1 (ru) 2006-02-24
SI1440059T1 (sl) 2008-08-31
RS25104A (sr) 2007-02-05
HK1072052A1 (zh) 2005-08-12
PL368919A1 (en) 2005-04-04
US20030087898A1 (en) 2003-05-08
HRP20040288A2 (en) 2004-12-31
JP2005511545A (ja) 2005-04-28
JP4155522B2 (ja) 2008-09-24
PA8556701A1 (es) 2003-07-28
HN2002000299A (es) 2002-11-21
GEP20084300B (en) 2008-02-11
DE60226161D1 (de) 2008-05-29
DE60226161T2 (de) 2009-07-02
KR20040048984A (ko) 2004-06-10
ES2302839T3 (es) 2008-08-01
US20070054950A1 (en) 2007-03-08
AU2002329557B2 (en) 2008-07-31
CN1610664A (zh) 2005-04-27
IL161157A0 (en) 2004-08-31
CN100368398C (zh) 2008-02-13
MA27141A1 (fr) 2005-01-03
CA2463264C (en) 2009-05-26
ECSP045077A (es) 2004-05-28
HUP0401884A2 (hu) 2005-01-28
MXPA04003730A (es) 2004-07-23
WO2003035622A1 (en) 2003-05-01
EA200400467A1 (ru) 2004-08-26
NO329092B1 (no) 2010-08-23
BR0213464A (pt) 2004-11-09
IS7187A (is) 2004-03-18
CR7317A (es) 2006-08-09
IL161157A (en) 2009-09-01
KR100621292B1 (ko) 2006-09-13
EP1440059B1 (en) 2008-04-16
AP2004003007A0 (en) 2004-06-30
PE20030610A1 (es) 2003-07-12
SV2004001363A (es) 2004-02-24
US20050171178A1 (en) 2005-08-04
GT200200216A (es) 2003-05-23
ATE392415T1 (de) 2008-05-15
DK1440059T3 (da) 2008-07-14
EP1440059A1 (en) 2004-07-28
ZA200402172B (en) 2006-09-27
PT1440059E (pt) 2008-05-16
JP2008069169A (ja) 2008-03-27
MY136580A (en) 2008-10-31
US7049335B2 (en) 2006-05-23
OA12711A (en) 2006-06-27
PY0225353A (es) 2004-05-03
TNSN04071A1 (fr) 2006-06-01

Similar Documents

Publication Publication Date Title
AR063680A1 (es) Derivados de pirazolo[1, 5-a]pirimidina, metodos e intermediario para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion de mglur5.
AR035532A1 (es) Diaminotiazoles, composiciones farmaceuticas que los comprenden, intermediarios para la preparacion de dichos compuestos, uso de dichos compuestos en la preparacion de medicamentos, y procesos para la preparacion de dichos compuestos
PE20231190A1 (es) Degradadores de moleculas pequenas de piperidinilo de helios y procedimientos de uso
AR063240A1 (es) Derivados de n-aril pirazol,composiciones farmaceuticas que los contienen y usos para el tratamiento de la diabetes tipo2,y enfermedades relacionadas.
TW200745029A (en) Sulfonamide derivatives exhibiting PGD2 receptor antagonism
AR035774A1 (es) Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento
AR037731A1 (es) Uso de ureas de benzotiazoles
AR043434A1 (es) Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
TW200734322A (en) Indole derivatives exhibiting PGD2 receptor antagonism
AR044016A1 (es) Compuestos de 4-fenil piperidina y sus usos como moduladores de receptores opioides
AR051091A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR051094A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
AR040031A1 (es) Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen
AR068877A1 (es) Derivados heterociclicos de imidazol
SE0104332D0 (sv) Therapeutic agents
AR076460A1 (es) Antagonistas del receptor cxcr3
AR065811A1 (es) Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos.
AR035732A1 (es) Derivados cromen-2-carboxilicos terapeuticos, uso de estos derivados para la preparacion de medicamentos, composicion farmaceutica, compuestos relacionados, y procesos para preparar estos compuestos relacionados
AR052682A1 (es) DERIVADOS DE 5, 6, 7, 8 - TETRAHIDROTIEN[2, 3 - B]QUINOLINA uTILES PARA INHIBIR LA ACTIVIDAD DE QUINESINA DE KSP, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS.
AR069691A1 (es) Derivados ciclopropilamina
AR085398A1 (es) Ureas asimetricas y usos medicos de las mismas
AR041193A1 (es) Formulaciones que comprenden un compuesto de indolinona
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento

Legal Events

Date Code Title Description
FB Suspension of granting procedure